GRANULES

June 3 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - RECEIVES US FDA EIR WITH VOLUNTARY ACTION INDICATED FOR CHANTILLY FACILITY

• GRANULES - FOUR FORM 483 OBSERVATIONS ISSUED DURING MARCH 30-APRIL 3, 2026 INSPECTION

Source text: ID:nNSE2qnM0s

Further company coverage: GRAN.NS

(([email protected];))

** Shares of India's Granules GRAN.NS jump 1.30% to 713.70 rupees

** Drugmaker's Q4 profit jumps 32.6% y/y to 2.02 billion rupees ($21.30 million), on strong demand for key products across major markets

** Total revenue from operations rises 21.7% y/y

** Europe's revenue share rose to 17% in Q4 FY26 from 8% in Q4 FY25

** Emkay said regulatory clearance of the Gagillapur facility in FY27 could boost formulation sales; introduces FY29 estimates and expects ~26% PAT CAGR over FY26–FY29

** GRAN rated "buy" on average by seven analysts, median PT: 685 rupees - data compiled by LSEG

** YTD, stock up ~18.6%

($1 = 94.8400 Indian rupees)

(Reporting by Bipasha Dey in Bengaluru)

(([email protected];))

** Granules India GRAN.NS reverses course, rises 3.23% to record high of 728 rupees

** Drugmaker's fourth quarter profit jumps 32.6% y/y to 2.02 billion rupees ($21.3 million) on strong demand for key products in its major markets and portfolio expansion

** Revenue rises 21.7% y/y to 14.71 billion rupees

** Around 2.84 mln shares traded vs 30-day avg of 1.17 mln

** Stock rated "buy" on avg; median PT is 685 rupees, per data compiled by LSEG

** YTD, GRAN up 17.82%

($1 = 94.7450 Indian rupees)

(Reporting by Surbhi Misra in Bengaluru)

(([email protected] | X: https://twitter.com/SurbhiMisra_ |;))

March 31 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - RECEIVES VAI CLASSIFICATION FOLLOWING US FDA INSPECTION

• GRANULES - INSPECTION IS NOW CLOSED, NO REGULATORY ACTION HAS BEEN RECOMMENDED

Source text: ID:nBSE1HyjKN

Further company coverage: GRAN.NS

(([email protected];;))

March 5 (Reuters) - Granules India Ltd GRAN.NS:

• PACKAGING FACILITY IN US GETS FDA EIR WITH NO ACTION INDICATED STATUS

Source text: ID:nnAZN4SJL8U

Further company coverage: GRAN.NS

(([email protected];))

** Shares of Granules India GRAN.NS rise 2.8% to 580.80 rupees

** Paracetamol maker's Q3 profit up 28% driven by strong demand in its key European and North American markets

** Co's Q3 consol profit up to 1.5 billion rupees vs 1.18 billion rupees y/y

** North America, which generates about two-thirds of the firm's revenue, logged a 14% jump in sales; Europe sales, which contribute 19% to topline, more than doubled

** Current production coming back on stream, ramp-up in new launches in the U.S. and other geographies, coupled with improved volumes- Dolat Capital

** GRAN down nearly 3% so far in January

(Reporting by Urvi Dugar in Bengaluru)

(([email protected];))

Jan 23 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES DEC-QUARTER CONSOL PROFIT 1.50 BILLION RUPEES

• GRANULES DEC-QUARTER CONSOL SALE OF PRODUCTS 13.78 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];))

Jan 8 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT RECEIVES FDA TENTATIVE APPROVAL FOR GENERIC AMPHETAMINE WITH 180-DAY EXCLUSIVITY

Source text: ID:nNSE826LQ6

Further company coverage: GRAN.NS

(([email protected];))

Dec 12 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT RECEIVES EIR FROM FDA

Source text: ID:nNSE7p3B0h

Further company coverage: GRAN.NS

(([email protected];))

Nov 13 (Reuters) - Granules India Ltd GRAN.NS:

• Q2 CONSOL PROFIT 1.31 BILLION RUPEES

• Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 12.97 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];;))

June 20 (Reuters) - Granules India Ltd GRAN.NS:

• BONTHAPALLY FACILITY COMPLETES US FDA INSPECTION

• FACILITY COMPLETED FDA INSPECTION WITH ONE 483 OBSERVATION

Source text: ID:nNSEbcFQWR

Further company coverage: GRAN.NS

(([email protected];;))

** Indian pharma stocks .NIPHARM gain 1.4%

** Donald Trump signs executive order directing drugmakers to lower prices of their medicines to align with what other countries pay

** But, the order was not as bad as feared, investors, analysts and drug pricing experts said

** Pharma stocks declined in early trade on Monday after Trump's announcement

** HDFC Securities says generic drugmakers unlikely to have any impact

** Adds Sun Pharma SUN.NS to see some impact of price ceiling on specialty products like psoriasis drug Ilumya and anti-baldness drug Leqselvi

** Glenmark Pharma GLEN.NS, Divi's Laboratories DIVI.NS climb 3% each; SUN rises 0.6%

** Lupin LUPN.NS, Granules India GRAN.NS and Biocon BION.NS gain 2.6%, 3.8% and 1.7% respectively

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

April 10 (Reuters) - Granules India Ltd GRAN.NS:

• CLOSING OF ACQUISITION OF SENN CHEMICALS

Further company coverage: GRAN.NS

(([email protected];))

March 25 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA - APPROVES INTERNAL RESTRUCTURING PLAN FOR US SUBSIDIARIES

Source text: ID:nNSE171DfJ

Further company coverage: GRAN.NS

(([email protected];))

March 18 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT GRANULES EUROPE HAS BEEN VOLUNTARILY DISSOLVED

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of pharma co Granules India GRAN.NS fall 2.4% to 460 rupees

** Stock among top losers on Nifty Pharma index .NIPHARM

** The US FDA issued a warning letter to co post inspection

** Reports says bird droppings and feathers were found on air purification units, ducts, tank etc

** Flagged issues including lack of written procedures for equipment cleaning, residues and microbial contamination in ducts, risking cross-contamination

** More than 2.2 mln shares change hands, 1.6x its 30-day avg

** Stock down ~21% YTD vs a ~15% drop in NIPHARM

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

** Shares of Granules India GRAN.NS slide as much as 7% to 471.5 rupees, their lowest in eight months

** Stock last down 6.6%; biggest pct loser on Nifty pharma index .NIPHARM, which is down 1.3%

** Pharma co's Gagillapur facility gets US FDA warning letter based on inspection conducted in August 2024

** The warning letter may temporarily impact the FDA review of pending product submissions from this site until the issue is resolved - GRAN

** The U.S. FDA classified the facility as "official action indicated", sending its shares down over 10%, on December 3

** GRAN stock has fallen ~11% since December 3

** Four brokerages' avg rating on stock is "strong buy", median PT is 657.5 rupees - data compiled by LSEG

** Year-to-date, GRAN down 14%; Nifty pharma index also 14% lower

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

** Shares of Granules India GRAN.NS climb 2.2% to 520 rupees

** Pharma co says it signed agreement to acquire Switzerland-based Senn Chemicals AG

** Co adds, acquisition is expected to close in the

first half of 2025

** Financial details of the deal was not disclosed

** Stock set to log gains after falling for two straight sessions

** Stock down ~14% YTD vs ~13% fall in broader Nifty Pharma index .NIPHARM

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Feb 21 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA LTD - TO ACQUIRE 100% EQUITY STAKE IN SENN CHEMICALS AG

• GRANULES: DEAL FOR 1.93 BILLION RUPEES

Source text: ID:nNSE1PXl9y

Further company coverage: GRAN.NS

(([email protected];;))

** Shares of Granules India GRAN.NS rise 3.6% to 565.2 rupees

** Pharma co said on Wednesday its Unit V facility received European Union good manufacturing practice certificate for active pharmaceutical ingredients (APIs) and finished dosages

** Certification implies co has been assessed and deemed to meet EU safety, health and environmental protection requirements

** Audit of the facility was done in Nov 2024, co says

** Stock gained 46% in 2024

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Jan 29 (Reuters) - Granules India Ltd GRAN.NS:

• UNIT V RECEIVES EU GMP CERTIFICATE

• EU AUTHORITY CONDUCTED AUDIT OF GRANULES INDIA UNIT V IN NOVEMBER 2024

Source text: ID:nBSE5nkvmM

Further company coverage: GRAN.NS

(([email protected];;))

Jan 24 (Reuters) - Granules India Ltd GRAN.NS:

• Q3 CONSOL PROFIT 1.18 BILLION RUPEES

• Q3 CONSOL TOTAL REVENUE FROM OPERATIONS 11.38 BILLION RUPEES

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];;))

Dec 17 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - ANNOUNCES FDA APPROVAL FOR ADHD TREATMENT, ADDRESSING DRUG SHORTAGES IN U.S

Source text: [ID:]

Further company coverage: GRAN.NS

(([email protected];))

Dec 4 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES - UPDATE ON US FDA INSPECTION AT GAGILLAPUR FACILITY

• GRANULES INDIA LTD - OAI CLASSIFICATION DOES NOT IMPACT ONGOING MANUFACTURING OR DISTRIBUTION

• GRANULES INDIA LTD - OAI STATUS MAY IMPACT REVIEW OF PENDING SUBMISSIONS FOR NEW PRODUCTS

Source text: ID:nnAPN2FLDZF

Further company coverage: GRAN.NS

(([email protected];))

** Shares of pharmaceuticals maker Granules India GRAN.NS close down 10.3%

** This is only the second session this year that the stock has declined by 10% or more

** Stock top loser on the Nifty Pharma index .NIPHARM, which slips about 0.1%

** US FDA classifies inspection co's Gagillapur facility as 'official action indicated' (OAI); the classification means regulatory or administrative actions are recommended

** Co says it has responded to all observations issued by the US FDA and voluntarily undertaken evaluation of facility, in consultation with external subject matter experts

** Trading vols at 18.4 mln, highest since mid-September

** GRAN stock has risen around 32% YTD, NIPHARM also up about 33%

(Reporting by Vijay Malkar)

(([email protected];))

** Shares of Granules India GRAN.NS climb as much as 3.2% to 590.5 rupees but trim gains to trade largely flat amid drop in Nifty 50 .NSEI, which is down 0.4% .BO

** Pharma co said a U.S. FDA inspection concluded at its unit's facility in Andhra Pradesh state with zero observations

** Facility secured an establishment inspection report with "No Action Indicated" status

** Stock up 44% YTD, its biggest annual gain since 2020

** Peers Aurobindo Pharma ARBN.NS and Alembic Pharma ALEM.NS up ~23% and 45% so far this year

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Nov 6 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES INDIA Q2 CONSOL PROFIT 972.3 MILLION RUPEES

• GRANULES INDIA Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 9.67 BILLION RUPEES

Further company coverage: GRAN.NS

(([email protected];))

** Shares of Granules India GRAN.NS fall as much as 16.9% to 562.10 rupees, mark sharpest intraday pct loss since March 23, 2020

** Pharmaceutical manufacturing co says several investors have sought clarification from co on U.S. FDA's observations on its Gagillapur facility

** Adds, it will work with FDA to address issues raised in the observations

** On Saturday, FDA inspection at this facility concluded with six observations

** Stock is witnessing its most active trading session since 2005 listing, with more than 35 mln shares change hands, 12.8x of 30-day avg

** Stock last down 16.6%, cutting YTD gains to 39.2%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Aug 20 (Reuters) - Granules India Ltd GRAN.NS:

• RECEIVES ANDA APPROVAL FOR GLYCOPYRROLATE ORAL SOLUTION

Source text for Eikon: ID:nBSE1TgfBl

Further company coverage: GRAN.NS

(([email protected];))

July 30 (Reuters) - Granules India Ltd GRAN.NS:

• GRANULES JUNE-QUARTER CONSOL NET PROFIT 1.35 BILLION RUPEES

• GRANULES JUNE-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 11.80 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: GRAN.NS

(([email protected];))